CPX-351 (a liposomal formulation of cytarabine and daunorubicin) is a chemotherapeutic agent for treatment of acute myeloid leukemia (AML). A phase 3 clinical trial of CPX-351 in pediatric AML (NCT04293562) is currently ongoing. Adult studies report that rash with CPX-351 is a frequent adverse event. However, the features of cutaneous side effects associated with CPX-351 in the pediatric population have not been well-described in the literature. Here we describe the characteristics and management of CPX-351 associated rash in the pediatric population. This is a retrospective case series of 45 patients who received CPX-351 at Texas Children’s Hospital from 2018-2022.